Gamida Cell (GMDA) Revenue & Revenue Breakdown
Gamida Cell Revenue Highlights
Latest Revenue (Y)
$1.78M
Latest Revenue (Q)
$890.00K
Gamida Cell Revenue by Period
Gamida Cell Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.78M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Gamida Cell generated $1.78M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Gamida Cell Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $890.00K | -19.89% |
| 2023-12-31 | $1.11M | 65.08% |
| 2023-09-30 | $673.00K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
Gamida Cell generated $890.00K in revenue during Q1 2024, up -19.89% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Gamida Cell Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| ARDX | Ardelyx | $124.46M | $73.22M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| BLRX | BioLineRx | $4.80M | $6.86M |
| GMDA | Gamida Cell | $1.78M | $890.00K |
| LXRX | Lexicon Pharmaceuticals | $1.20M | $1.65M |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| IBRX | ImmunityBio | $622.00K | $1.05M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
GMDA Revenue FAQ
What is Gamida Cell’s yearly revenue?
Gamida Cell's yearly revenue for 2023 was $1.78M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GMDA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Gamida Cell’s quarterly revenue?
Gamida Cell's quarterly revenue for Q1 2024 was $890K, a -19.89% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.11M, a 65.08% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). GMDA's quarterly revenue for Q3 2023 was $673K, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Gamida Cell’s revenue growth rate?
Gamida Cell's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.